Table 3.
Risk factors for recurrent severe neutropenic events.
| Variables | Univariable Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| Odds Ratio (95% CI) | p-Value | Odds Ratio (95% CI) | p-Value | |
| Age ≥ 65 years (vs. <65) | 0.67 (0.07–6.17) | 0.72 | - | |
| BMI ≥ 25 (vs. <25) | 1.61 (0.75–3.46) | 0.22 | - | |
| BSA ≥ 1.65 (vs. <1.65) | 0.85 (0.38–1.90) | 0.70 | - | |
| ER: positive over negative | 0.82 (0.31–2.18) | 0.69 | - | |
| PR: positive over negative | 1.40 (0.65–3.03) | 0.39 | - | |
| HER2: positive over negative | 1.22 (0.46–3.27) | 0.69 | - | |
| Cancer stage: III over I–II | 1.20 (0.52–2.77) | 0.66 | - | |
| CV diseases present over absent | 2.10 (0.84–5.21) | 0.11 | 1.58 (0.58–4.29) | 0.37 |
| DM present over absent | 0.79 (0.21–3.06) | 0.74 | - | |
| Post-menopause over pre-menopause | 1.69 (0.79–3.62) | 0.17 | 2.02 (0.85–4.80) | 0.11 |
| Basal Hb < 12 g/dL | 0.78 (0.30–2.01) | 0.61 | - | |
| Basal WBC count < 4000/μL | 0.44 (0.05–3.74) | 0.45 | - | |
| Basal ALT or AST > 40 IU/L | 0.69 (0.21–2.22) | 0.53 | - | |
| Secondary prophylaxis of G-CSF | 0.20 (0.08–0.47) | <0.01 | 0.17 (0.07–0.43) | <0.01 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BSA, body surface area; CV, cardiovascular; DM, diabetes mellitus; ER, estrogen receptor; G-CSF, granulocyte colony-stimulating factor; Hb, hemoglobin; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; WBC, white blood cell.